Clinuvel Pharmaceuticals Ltd.
- BID
6.35
- ASK
6.586
- 1,441 Units750 Units
- 07/21, 16:34:23 PM
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
3.09%
Market Cap
-
P/E Ratio
14.37
Dividend Yield
0.48 %
Earnings per Share
0.43 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | ||
| LAST PRICE | 6.35 G | 0 Units |
| PRICE DETERMINATION TIME | 07/21/2026 / 04:33:09 PM | |
| DAILY VOLUME (UNITS) | 500 | |
| DAILY HIGH / LOW | 6.35 | 6.066 |
| PREV. DAY'S PRICE | 6.402 | (07/20) |
| CHANGE DAY BEFORE | -0.05 | -0.81 % |
| 52 WEEK HIGH / LOW | 8.075 (08/27) | 4.931 (06/10) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | 0.40 | 0.43 | 0.43 | 0.44 | 0.45 |
DIVIDENDS PER SHARE | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 |
DIVIDEND YIELD IN % | 0.28 % | 0.33 % | 0.48 % | - | - |
DIVIDEND GROWTH IN % | 24.87 % | -5.80 % | -1.72 % | - | - |
PRICE - EARNINGS RATIO | 28.87 | 21.49 | 14.37 | 14.16 | 14.01 |
PRICE - BOOK RATIO | 5.37 | 3.79 | 2.16 | - | - |
PRICE - SALES RATIO | 11.83 | 8.89 | 5.50 | - | - |
PRICE - CASH FLOW RATIO | 25.10 | 21.17 | 12.73 | - | - |
Master Data
| WKN | A0JEGY |
| ISIN | AU000000CUV3 |
| SYMBOL | UR9 |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | CLINUVEL PHARMACEUTICA |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | - |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | - |
| MARKET CAPITALISATION | - |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | 2.66 % | 1.59 % | 13.59 % | -9.64 % | 3.09 % | -42.01 % | -63.06 % | -8.35 % |
| HIGH | 6.56 | 6.56 | 6.56 | 7.06 | 8.08 | 12.89 | 27.39 | 7.33 |
| LOW | 5.92 | 5.78 | 4.93 | 4.93 | 4.93 | 4.93 | 4.93 | 4.93 |
Dividende
pro Aktie
Company profile
Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The firm engages in the development of SCENESSE, its proprietary photoprotective drug. It also offers drugs for the treatment of various skin disorders. The company was founded by Robert Thomas Dorr on December 14, 1999 and is headquartered in Melbourne, Australia.
Structured products for Clinuvel Pharmaceuticals Ltd.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.